FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF AN ECONOMIC MODEL

被引：0
|
作者：
Kelleher, C. [1 ]
Snedecor, S. J. [2 ]
Botteman, M. F. [2 ]
Lee, R. [3 ]
Najib, H. [4 ]
Weinstein, D. [5 ]
Trocio, J. N. [6 ]
机构：
[1] St Thomas Hosp, London, England
[2] Pharmerit N Amer LLC, Bethesda, MD USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[4] Pfizer Ltd, Surrey, England
[5] Pfizer France, Paris, France
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67122-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A652 / A652
页数：1
相关论文
共 50 条
  • [1] Fesoterodine for the treatment of overactive bladder
    Belavic, Jennifer M.
    [J]. NURSE PRACTITIONER, 2009, 34 (08): : 14 - 15
  • [2] Fesoterodine for the Treatment of Overactive Bladder
    Tzefos, Maria
    Dolder, Christian
    Olin, Jacqueline L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (12) : 1992 - 2000
  • [3] AN ECONOMIC EVALUATION OF FESOTERODINE IN THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN KOREA
    Jo, C.
    Lee, S. J.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A200 - A200
  • [4] Role of fesoterodine in the treatment of overactive bladder
    Mansfield, Kylie J.
    [J]. RESEARCH AND REPORTS IN UROLOGY, 2010, 2 : 1 - 9
  • [5] Evaluation of fesoterodine fumarate for the treatment of an overactive bladder
    Mock, Stephen
    Dmochowski, Roger R.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (12) : 1659 - 1666
  • [6] Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden
    Prutz, C.
    Snedecor, S.
    Botteman, M.
    Trocio, J.
    Weinstein, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [7] Comparison of solifenacin and fesoterodine in treatment of overactive bladder
    Ercan, Onder
    Kostu, Bulent
    Bakacak, Murat
    Aytac-Tohma, Yusuf
    Coskun, Bora
    Avci, Fazil
    Efe, Erkan
    [J]. SAUDI MEDICAL JOURNAL, 2015, 36 (10) : 1181 - 1185
  • [8] Flexible dose fesoterodine in the treatment of overactive bladder (OAB)
    Tubaro, Andrea
    De Nunzio, Cosimo
    [J]. BJU INTERNATIONAL, 2013, 112 (03) : 281 - 282
  • [9] ECONOMIC IMPACT OF USING FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER IN VULNERABLE ELDERLY POPULATION IN THE UNITED STATES
    Qin, L.
    Luo, X.
    Zou, K. H.
    Snedecor, S. J.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S412 - S413
  • [10] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Angulo, Javier C.
    Valpas, Antti
    Rejas, Javier
    Linden, Kari
    Kvasz, Marion
    Snedecor, Sonya J.
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (05) : 297 - 307
12345